Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the thiazolecarboxamide class. It is known as an experimental Spleen tyrosine kinase (SYK) inhibitor and has been referenced in chemical and pharmacological databases as a tool compound for research purposes. Its primary mechanism of action is believed to be inhibition of SYK, a non-receptor tyrosine kinase involved in immune cell signaling pathways. There are no approved therapeutic indications or marketed formulations for this molecule; it is primarily used in preclinical studies to investigate SYK-related biology[1][2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl-1,3-thiazole-5-carboxamide.